Latest News

  • TECHNOLOGY

    18 Feb 2026

    How the Cloud Powers the Next mRNA Breakthrough

  • INSIGHTS

    16 Feb 2026

    Can Europe Win the mRNA Cancer Race?

  • REGULATORY

    12 Feb 2026

    FDA Refusal-to-File Resets mRNA Flu Strategy

  • INNOVATION

    11 Feb 2026

    Britain’s Bet On Better RNA Factories

Moderna and Recordati Bet on mRNA Beyond Vaccines

Syringe labeled Moderna mRNA-3927 with Recordati logo in background

PARTNERSHIPS

10 Feb 2026

Moderna and Recordati partner on an mRNA therapy for propionic acidemia, combining resources to accelerate development

BioNTech and CureVac company branding displayed outside offices

PARTNERSHIPS

3 Feb 2026

BioNTech–CureVac Deal Marks a New Era for mRNA

BioNTech’s CureVac buyout shows how scale and integration are now driving competition in the mRNA industry

Biotech executives mark a major corporate milestone during a Nasdaq ceremony

PARTNERSHIPS

20 Jan 2026

GSK’s $2.2B Bet Signals a New Phase in Allergy Drug Races

GSK’s acquisition of RAPT spotlights late-stage allergy drugs, hints at a cautious M&A revival, and raises the stakes in immunology

Bristol Myers Squibb corporate sign outside company campus

INSIGHTS

19 Jan 2026

BMS–Orbital Deal Signals a Sharper Bet on In Vivo RNA

Bristol Myers Squibb’s Orbital buy shows how big pharma is methodically building RNA muscle beyond vaccines

Merck and Moderna logos displayed on a white background

RESEARCH

16 Jan 2026

mRNA Developers Regroup After Trial Setbacks

After late-stage failures, mRNA leaders narrow pipelines, double down on vaccines and cancer, and adopt tougher capital discipline

Oncovita company logo linked to RNA oncology drug development

PARTNERSHIPS

13 Jan 2026

AI Alliance Refines RNA Cancer Drug Discovery

Oncovita teams with Infinitusbio.AI to use digital cell modeling to sharpen early decisions in RNA oncology research

Aktis Oncology logo displayed over a laboratory research setting

INVESTMENT

12 Jan 2026

A New Pulse in Biotech IPOs Starts With Oncology

Aktis Oncology’s planned Nasdaq debut, backed by Eli Lilly, suggests investors are cautiously returning to targeted cancer innovation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.